Dr Christopher Richards
Chris was appointed Chairman of Nanoco Group plc in May 2016, having joined the Board as a Non-executive Director in November 2015. Following a successful international career in the agrochemical and life sciences industries, Chris has become a highly experienced non-executive director and business adviser. He currently holds a number of executive and non-executive roles at quoted and private businesses. He is the executive chairman of Plant Health Care plc (AIM: PHC) and a non-executive director of Origin Enterprises plc (AIM: OGN).
He is also a non-executive director at Cibus Global Inc, a privately owned US biotechnology company, and the founder of Talestris Ltd, his consultancy business. Christopher is the former chief executive officer of Arysta LifeScience, a Japan-based agrochemical business which grew rapidly under his leadership. After stepping down as CEO in 2009, he became Arysta LifeScience’s non-executive chairman until the sale of the business in 2015 to Platform Specialty Products. After gaining his DPhil from the University of Oxford in Biological Science, Chris worked as a research scientist for four years. He began his executive career in 1983 in the Plant Protection Division at Imperial Chemical Industries plc, which later became Syngenta. During 20 years, he has lived in various countries including Colombia and Japan and led international marketing and commercial functions.
Dr Michael Edelman
Chief Executive Officer
Nanoco is led by Dr Michael Edelman who joined the Group twelve years ago in September 2004. Michael led the initial fundraising, spun Nanoco out of the University of Manchester, floated the Group on the London Stock Exchange in 2009 and grew Nanoco into the world-leading quantum dot player it is today. Prior to Nanoco, Michael held a number of executive roles, including having responsibility for licensing the technology developed by GE/Bayer joint venture, Exatec LLP, vice president and managing director at yet2. com, commercial director at Colloids Ltd and business manager at Brunner Mond & Co Ltd. Michael started his career with ICI, has a PhD in organometallic chemistry from the University of Sussex, UK, and an undergraduate degree in classics and chemistry from Tufts University, Boston, MA, USA.
Chief Operating Officer
Keith is a highly experienced chemicals industry executive. He began his career with ICI, working in R&D and manufacturing, before joining The Dow Chemical Company (“Dow”) in 1989 as a sales manager in its London office. He went on to lead progressively bigger and more complex specialty chemical businesses around the world, living in Germany, Switzerland and the USA. In 2006 Keith returned to the UK as managing director for Dow UK, Ireland & Nordic. He held this position until 2013 and, from 2006 to 2011, he was concurrently CEO-global business director of Haltermann, a specialty chemicals subsidiary of Dow. Keith, who graduated in chemistry at Imperial College, London, is an Honorary Fellow of the Royal Society of Chemistry. He has held a number of industry offices including President of the Chemical Industries Association between 2011 and 2013.
Chief Financial Officer
David is a chartered accountant with considerable operational, commercial and strategic experience gained at a number of businesses quoted on the London Stock Exchange. He joined Nanoco from the role of chief financial officer of Inspired Capital plc, an AIM-listed finance provider. After qualifying as a chartered accountant David joined the Newcastle office of Price Waterhouse (now PwC), where he worked for nine years in audit and business advisory services. He then spent eleven years as the finance director of Drew Scientific Group plc, a medical diagnostics company on the Main Market. His next role was at the AIM-traded IT business eg Solutions plc, after which he became chief financial officer of Renovo Group plc, the Manchester-based biotechnology company that later became Inspired Capital plc.
Dr Nigel Pickett
Chief Technology Officer
Nanoco’s technology team is led by Nigel who is a co-founder of Nanoco and inventor of Nanoco’s key quantum dot scale up technology. In 2000 he moved to Manchester where he co-founded Nanoco Technologies in 2001. Nigel has co-authored over 70 academic papers, is an inventor on 150 patents and pending. He has a passion and experience in taking research work from the academic bench through to full commercialisation. Nigel graduated from Newcastle University in 1991 and chose to remain at Newcastle to pursue a PhD in the field of main group organometallics. After graduation in 1994 he undertook a postdoctoral fellowship at St. Andrews University, Scotland, in the field of precursor design for metalorganic vapour phase epitaxy (“MOVPE”) growth and synthesis of nanoparticles using chemical vapour deposition (“CVD”) techniques. In 1996 he won a Japan Society for the Promotion of Science (“JSPS”) fellowship and spent the following year working at Tokyo University of Agriculture and Technology, Japan. In 1998 he became a research fellow at Georgia Institute of Technology, USA, working on the design and evaluation of precursors used in MOVPE.
Robin Williams was appointed to the Board on 9 July 2014. Robin has an engineering science degree from Oxford University and qualified as ACA. He spent the early part of his career in financial advisory, before co-founding Britton Group plc as CEO. He built this to a successful international packaging group which was sold to a US trade buyer in 1998. He then became an executive director of Hepworth plc, a substantial building products group, as managing director of one division, also as group director for strategy and rationalisation. After leading a non-core business disposal programme, he played a key part in the sale of the group to a German trade buyer. For the past ten years, he has been a non-executive director or chairman in a wide variety of public, public sector and private companies and has been chairman of three plc audit committees. Robin is Chairman of the Audit Committee and a member of the Remuneration and Nominations Committees.
Non-Executive Senior Independent Director
Brendan is a highly experienced chemicals industry executive with 40 years of industry and leadership experience. Most recently, he was Chief Executive Officer of Ciba Inc., the major international chemicals company acquired by BASF in 2009. During his executive career he worked for many years at the Ciba-Geigy Group and then at Ciba Inc., which was formed in 1998 when Ciba-Geigy separated its chemical and pharmaceutical interests. Brendan joined Ciba-Geigy in 1971 in Ireland and went on to hold many senior international positions at Ciba-Geigy and at Ciba Inc. in locations including Switzerland, China, Hong Kong and Singapore. A qualified accountant, he is currently a non-executive director of Ashland Inc., a global speciality chemical company quoted on the New York Stock Exchange.